Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative colitis diagnosed by routine clinical, radiographic, endoscopic and pathologic criteria (preferably confirmed by colonoscopy and pathology records within last 2 years or if unavailable, will need approval by medical monitor) Active mild-moderate UC as determined by sigmoidoscopy within approximately 3 days of randomization to study~Exclusion Criteria:~1. Fever \> 38.3°C~2. Known or suspected toxic megacolon and/or known small bowel ileus~3. Known history of Crohn's disease~4. Subjects with serum albumin \<2.5 g/dL at baseline~5. CMV polymerase chain reaction (PCR) positive from blood plasma at screening~6. Known stool studies positive for ova and/or parasites or stool culture within the 30 days before enrollment~7. Subjects on cyclosporine or triple immunosuppression, Triple immunosuppression will include any three of the following classes of drugs taken in combination: steroids (i.e., prednisone/budesonide/budesonide MMX), immunosuppressant (i.e., methotrexate/azathioprine/6-mercaptopurine), and/or other immunosuppressant (i.e., tacrolimus, cellcept).~8. Biologic medication (infliximab/ adalimumab/ golimumab/ certolizumab/vedolizumab/ustekinumab/natalizumab) use within 3 months prior to screening~9. Known active malignancy except for basal cell skin cancer, squamous cell skin cancer~10. Subjects with previous colectomy, ostomy, J-pouch, or previous intestinal surgery (excluding cholecystectomy, appendectomy)~11. Subjects with known history of celiac disease or gluten enteropathy~12. Subjects with Clostridium difficile positive stool at Screening Visit~13. Antibiotic use within the prior 1 month before randomization~14. Expected to receive antibiotics within 8 weeks of signing the Informed Consent Form (ICF) (i.e., for planned/anticipated procedure)~15. Received an investigational drug within 1 month before study entry~16. Received an investigational antibody or vaccine within 3 months before study entry~17. Previously enrolled in a SER-109/SER-287 study~18. Received an FMT within the last 6 months~19. Subjects with anatomic or medical contraindications to flexible sigmoidoscopy, including but not necessarily limited to toxic megacolon, gastrointestinal (GI) fistulas, immediate post-operative status from abdominal surgery, severe coagulopathy, large or symptomatic abdominal aortic aneurysm, or any subject where study physician deems subject at significant risk of complications of flexible sigmoidoscopy~20. Unable to stop steroid enemas or suppositories or mesalamine enemas or suppositories before screening visit~21. Unable to stop opiate treatment unless on a stable dose and no increase in dose planned for the duration of the study~22. Unable to stop probiotics before screening visit~23. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with medical monitor)~24. Known allergy or intolerance to oral vancomycin~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Weekly SER-287, after Placebo Pre-Treat. (Type: EXPERIMENTAL): Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
- Daily placebo, after Placebo Pre-Treat. (Type: PLACEBO_COMPARATOR): Placebo pre-treatment, followed by once daily placebo for 8 weeks
- Daily SER-287, after Vanco. Pre-Treat. (Type: EXPERIMENTAL): Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
- Weekly SER-287, after Vanco. Pre-Treat. (Type: EXPERIMENTAL): Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).